Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ilypsa
Finance Watch: $2.2bn In New Funding Sources In February, So Far
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Eisai Exits Dermatology Through Roivant Deal
Eisai has followed in the footsteps of Japanese peer Astellas by divesting assets in the dermatology area, this time through a deal with Roivant for a clinical stage atopic dermatitis therapy that it sees as no longer fitting into its strategic priorities.
Relypsa’s Potassium-Lowering Drug Clears FDA, But Dosing Warning Could Impact Use
Boxed warning says other oral drugs should be taken at least 6 hours before or after; Veltassa to launch in January with support from Sanofi’s sales force.
Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings
CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.